4 January 2021 - - The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for Dexaven (dexamethasone phosphate) solution for injection, 4 mg/ml, for the treatment of COVID-19 in adult and adolescent patients (12 years of age and older weighing at least 40 kg) who require oxygen therapy, Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) said.

Dexaven is a corticosteroid that reduces inflammation.

Dexamethasone-containing products in the United States are not approved as a treatment for COVID-19 by the US Food and Drug Administration. Patients should only use these products in accordance with their approved label and the directions of their doctor.

Bausch Health Companies develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.